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Abstract 
The present study compares the extrapyramidal and neurochemical effects of 
clozapine and risperidone in rat caudate (corpus striatum) and nucleus 
accumbens (ventral striatum) dose-dependently. Animals injected with 
clozapine (2.5, 5.0 and 10.0 mg/kg IP) or risperidone (1.0, 2.5 and 5.0 mg/kg IP) 
in acute were sacrificed 1 h later to collect brain samples. Extrapyramidal side 
effects (EPS) in terms of locomotor activity and catalepsy were monitored in 
each animal after the drug or vehicle administration. Maximum cataleptic 
potentials were found only at high doses of clozapine (10.0 mg/kg; 60%) and 
risperidone (5.0 mg/kg; 100%). Neurochemical estimations were carried out by 
HPLC-EC. Both drugs at all doses significantly (p<0.01) increased the 
concentration of homovanillic acid (HVA), a metabolite of DA, in the caudate 
nucleus and decreased in nucleus accumbens. Levels of Dihydroxyphenylacetic 
acid (DOPAC) significantly (p<0.01) increased in the caudate by clozapine 
administration and decreased in the nucleus accumbens by the administration 
of both drugs in a dose-dependent manner. 5-Hydroxyindoleacetic acid 
(5-HIAA), the predominant metabolite of serotonin significantly decreased in the 
caudate and nucleus accumbens in a similar fashion. Levels of tryptophan 
(TRP) were remained insignificant in caudate and nucleus accumbens by the 
injections of two drugs. In caudate, clozapine and risperidone administrations 
significantly (p<0.01) decreased HVA/DA ratio and increased DOPAC/DA ratio 
in nucleus accumbens at all doses. The findings suggest the evidence for 260  F. Batool, M. A. Haleem and D. J. Haleem:   
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DA/5-HT receptor interaction as an important link in the lower incidence of EPS. 
The possible role of serotonin1A  receptors in the pathophysiology of schizo-
phrenia is also discussed. 
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Introduction 
Schizophrenia is a clinical syndrome with diverse manifestations. Dopamine (DA) D2 
receptor antagonism is postulated to be a key to antipsychotic efficacy in the treatment of 
schizophrenia [1]. Typical antipsychotic drugs with a high extrapyramidal motor side-
effects (EPS) liability markedly increase extracellular dopamine in the caudate-putamen, 
while atypical antipsychotic drugs with a low incidence of EPS have less pronounced 
stimulating actions on corpus striatal dopamine [2, 3]. Therefore, it has been suggested 
that the EPS liability of antipsychotic drugs (APD) is correlated with their ability to increase 
extracellular dopamine in the caudate-putamen [3]. The caudate nucleus is highly 
innervated by dopamine neurons. These neurons originate mainly from the ventral 
tegmental area (VTA) and the substantia nigra pars compacta (SNc) [4]. There are also 
additional inputs from various association cortices. Nucleus accumbens (NAcc) is another 
basal ganglia structure probably mediating EPS of typical antipsychotic drugs [5]. 
Therefore, the present study sought to determine whether extracellular dopamine in the 
NAcc might be a further indicator to differentiate neurochemical actions of typical and 
atypical antipsychotic drugs. The ability of antipsychotic drugs to affect 5-HT1A receptor 
function has been widely suggested to contribute to their therapeutic properties [6]. 
Atypical antipsychotic drugs related to clozapine, improve psychosis, cognition and 
negative symptoms, while producing minimal EPS, in patients with schizophrenia [7]. This 
appears to be mediated mainly through the combined effect of relatively more potent 
blockade of 5-HT1A receptors, located on cortical and hippocampal glutamatergic and 
GABAergic neurons, as well as cell bodies of the mesolimbic and mesocortical dopamine 
(DA) neurons, and weaker blockade of D2 receptors in the ventral and dorsal striatum and 
pyramidal neurons in cortical areas, as well as the cell bodies of DA neurons [7, 8]. The 
implications of EPS reduction touch virtually every domain of pathology in schizophrenia, 
including short- and long-term movement disorders, negative symptoms, noncompliance, 
relapse rate, cognitive dysfunction, and dysphoria [9]. The important goal of the present 
research on atypical neuroleptics is to develop novel compound(s) with antipsychotic 
potential with a low incidence of EPS. 
A majority of schizophrenic patients respond to classical neuroleptic drugs which are 
believed to act largely via blockade of dopamine (DA) D2 receptors in limbic structures 
[10]. However, a significant proportion do not respond to conventional D2 receptor blocking 
drugs or show a rather incomplete therapeutic effect, particularly on negative and cognitive 
symptoms [11]. An examination of clinical literature shows that haloperidol is very likely to 
produce EPS, clozapine is relatively unlikely and risperidone is somewhat mild in terms of 
the production these effects [12]. In comparison with classical neuroleptics atypical 
antipsychotic drugs such as for example clozapine and risperidone have been found to   Relationship of Clozapine and Risperidone in Caudate and Nucleus Accumbens  261 
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posses improved efficacy against negative symptomatology and cause a reduced 
incidence of EPS in clinically effective doses [13]. The present work was undertaken in an 
attempt to gain further insights into the mechanisms of action of atypical antipsychotic 
drugs as an icon with low propensity towards EPS in rats. Clozapine, the first of the 
atypical antipsychotic, has been reported to be effective in approximately one third or two 
third of patients with treatment resistant disease [12, 13]. The atypical is reported to be 
effective for the treatment of both positive and negative symptoms of schizophrenia. It also 
produces smaller EPS than typical neuroleptics. However, clozapine has the potential for 
fatal adverse effect: agranulocytosis [14], a sudden drop in white cell count that could 
leave the patient vulnerable to overwhelming infections [15]. Obviously, a goal of current 
neuroleptic research is to develop antipsychotic compounds with low incidence of EPS and 
agranulocytosis. One of the approaches in this context has been to determine 
neurochemical/ pharmacological correlates of clozapine and other atypical neuroleptics. A 
distinguished element of the pharmacology of clozapine is its affinity for serotonin 
(5-hydroxytryptamine; 5-HT) receptors particularly 5-HT2A, 5-HT2C and 5-HT1A receptors 
[16, 17]. The atypical has lower affinity for dopamine (DA) D2 receptors than traditional 
antipsychotics [4,  11]. Although clozapine is recognized as the prototypal atypical anti-
psychotic drug, there are no well defined criteria for classifying newly developed 
antipsychotics as atypical. Meltzer [12] suggested defining an antipsychotic as atypical 
based on antagonistic actions at both, D2 and 5HT2 receptors as well as clinical criteria of 
minimal induction of EPS at therapeutic doses.  
The present contribution focuses on the possible role of different 5-HT receptors in the 
modulation of atypical neuroleptic mechanism of action other than dopamine receptors. 
Following the discovery of 5HT2 (now termed 5HT2A) receptors, it was reported that several 
neuroleptics bound to both 5HT2A and D2 receptors [12, 13]. Risperidone provided further 
evidence that potent 5HT2A antagonism combined with milder D2  antagonism [12,  13] 
resulted in significantly improved clinical properties [12,  13]. Indeed, in addition to 
successful treatment of the positive symptoms, risperidone markedly improved the 
negative symptoms of schizophrenia with a low liability of EPS [14–16]. Risperidone, a 
benzisoxazol derivative, is an antipsychotic agent, which combines potent serotonin 5HT2 
and dopamine D2 receptor antagonism [14, 15] and has been introduced in the wake of 
clozapine induced toxicity. Moreover, clinical studies have revealed that risperidone 
displays a beneficial antipsychotic action, improving both positive and negative symptoms, 
while having a low propensity to induce EPS [16, 17]. Besides 5-HT2 and DA-D2 receptors, 
risperidone exhibits rather high affinity for central α1 adrenergic and H1 histamine receptors 
and a moderate affinity for α2 adrenergic receptors [12, 14–16]. Tissue measurements of 
regional DA and 5-HT metabolism in the rat brain have indicated that risperidone affects 
DA turnover in both mesolimbic and nigrostriatal terminal regions and, to some extent, also 
5-HT metabolism in these target areas [12].  
The aim of the present study was, therefore, to compare the dose-response effects of 
clozapine and risperidone on extrapyramidal motor functions and on DA metabolism in rat 
caudate and nucleus accumbens. Homovanillic acid (HVA) and dihydroxyphenyl acetic 
acid (DOPAC) are the predominant metabolites of DA, Therefore, in the present study 
effects of clozapine and risperidone are also compared on HVA/DA and DOPAC/DA ratios 
in caudate and nucleus accumbens of a rat brain. 262  F. Batool, M. A. Haleem and D. J. Haleem:   
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Materials and Methods  
Experimental Animals 
The protocol for experimentation was approved and performed in strict accordance with 
the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal 
Resources on Life Sciences, US National Research Council, 1996) and the Institutional 
Animal Ethics Committee (IAEC). Male Albino-Wistar rats with an average weight of 
180±20 g, purchased from Agha Khan University (AKU) were fed on standard diet and 
water  ad libitum. The animals were group-housed (two rats per cage) in an 
environmentally controlled room (ambient temperature 24±2°C and relative humidity 
55±5%) on a 12:12 h light/ dark cycle (lights on at 7:00 A.M.). A 5-day acclimatization 
period was allowed before animals were used in experiments. After this period, and 24 h 
before the behavioral tests, the animals were individually housed in an environmentally 
controlled test room in transparent Perspex cages (dimensions 26×26×26 cm W×L×H). 
The guidelines of IAEC, Pakistan the governing body for animal experimentations in 
Pakistan, were strictly adhered to during the whole animal experimentation protocol.  
Drugs and Injections 
Clozapine (Sigma) was dissolved in a minimum volume of 0.1 M acetic acid and pH 
adjusted to 6.5 by NaOH and diluted with physiological saline (0.9% NaCl) to 
concentrations of 2.5 mg/ml, 5.0 mg/ml and 10.0 mg/ml IP in volumes of 1ml/kg body 
weight. Risperidone (Janssen) was dissolved in 0.4M tartaric acid and pH adjusted to 6.5 
by NaOH and diluted with saline to the desired concentrations of 1.0 mg/ml, 2.5 mg/ml and 
5.0 mg/ml IP in volumes of 1.0 ml/kg body weight. Control animals received equal volume 
of vehicle (0.1 M acetic acid, 0.1 M NaOH and/or 0.4 M tartaric acid and saline in the ratio 
of 1: 1: 8). The animals were injected in a balance design between 10:00 and 11:00 h. 
Motor activity monitored for 10 min starting 10 min after injections. Catalepsy effects of the 
drugs were scored for a cut off time of 3 min starting 30 min post injections and animals 
were killed to collect brain samples 1 h after injections. 
Behavioral Procedures 
Dose-Dependent Effects of Clozapine and Risperidone on Locomotion 
Motor-related effects of the drugs were monitored in Perspex activity cages. Animals were 
transferred in Perspex activity cages (26x26x26 cm) with saw dust covered floor 15 min 
before injecting the saline or drug. Experiment was conducted in a separate quiet room. 
Motor activity in the activity box was monitored under white light as numbers of cage 
crossings/ 10 min starting 10-min post injections in all groups of rats in a balanced design 
[18]. 
Dose-Dependent Effects of Clozapine and Risperidone on Catalepsy 
Catalepsy, defined as the acceptance and retention of abnormal posture, was measured 
by means of a bar test. Bar test determinations were carried out by gently removing rats 
(n=12) from their home cages and placing their forepaws over a horizontal bar, fixed at a 
height of 10 cm with heads of animals upwards on an inclined surface at an angle of 60° 
with the hind limbs abducted [4, 18]. The lapse of time during which the animal retained 
this position was recorded by measuring the time from the placement of the rat until 
removal of one of its forepaws. An animal to be tested was placed on an inclined surface   Relationship of Clozapine and Risperidone in Caudate and Nucleus Accumbens  263 
Sci Pharm. 2010; 78: 259–274. 
(26 x 40cm, 60° inclination) for cut off time 3 min. A control rat changes its position 
immediately on the inclination. Time (sec) as drug or saline injected animals remained 
immobile on the inclination was monitored. Animals not moving on the surface up to 3 min 
were kept back in their cages. Cataleptic score was calculated as {Latency of movement 
(s)/ cut-off time (180 s)} 100. 
Neurochemical Analysis 
Dissection of Caudate and Nucleus Accumbens 
Saline, clozapine or risperidone injected animals were killed 1 h post injections. The 
dissection procedure was essentially same as described before [18, 19]. A fresh brain was 
dipped in ice-cold saline and placed with its ventral side up in the molded cavity of a brain 
slicer. Fine fishing line wire was inserted into the slots of the slicer to give slices of 2 mm 
thickness. The slice containing caudate and nucleus accumbens was transferred to a 
glass plate kept on ice. Punches of 2.5 mm diameter were made bilaterally in the upper 
and lower sides of the slice to collect the desired brain regions. The striatum also known 
as striate body, neostriatum or striate nucleus is a subcortical (i.e., inside, rather than on 
the outside) part of the telencephalon/cerebrum. It is the major input station of the basal 
ganglia system. In primates (including humans), the striatum is divided by a white matter 
tract called the internal capsule into two sectors called the caudate nucleus (corpus 
striatum) and nucleus accumbens (ventral striatum). The collected brain regions were 
immediately stored for the biogenic amine assay at −70°C for the estimation of DOPAC, 
DA, HVA and 5-HIAA levels by High performance liquid chromatography with 
electrochemical detection (HPLC-EC) [18].  
HPLC-EC Analysis  
Biogenic amines and their major metabolites were extracted with 150 μl of perchloric acid 
(HClO4; 70 %) from brain tissue punches (< 250 μg) using a simple one-step sample 
preparation method (19). A 5 μm (particle size) ODS column (4.0 mm i.d. and 250 mm 
length) was used. Mobile phase comprised of proportions of methanol (CH3OH; 14 %), 
octyl sodium sulphate (OSS; 0.023 %) and ethylenediaminetetraacetic acid (EDTA; 0.0035 
%) in 0.1M phosphate buffer of pH 2.9 was passed through the column at constant flow 
rate (1.0 ml/min) with the help of Waters 510 HPLC pump (Waters Corporation, US). 
Electrochemical detection was achieved on Schimadzu L-EC 6A detector (Shimadzu 
Corporation, Japan) at an operating potential of 0.8 V. Tryptophan was determined in a 
separate run at an operating potential of 1.0 V (18, 19).  
Statistical Analysis 
Results are presented as means ± S.D. Statistical analysis was performed using one-way 
ANOVA (analysis of variance) and Post hoc comparison was done by the Newman-Keuls 
test. p values < 0.05 were considered statistically significant.  
Results 
Figure 1 shows the dose-response relationship of clozapine and risperidone on locomotor 
activity and cataleptic potential in rats. ANOVA (df 3,12) showed significant effects of 
risperidone (1.0, 2.5 and 5.0 mg/kg) on motor activity (F=65.7 p<0.01) and catalepsy 
(F=226.9 p<0.01). Effects of clozapine (2.5, 5.0 and 10.0 mg/kg) on motor activity (F=8.0 264  F. Batool, M. A. Haleem and D. J. Haleem:   
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p<0.01) and catalepsy (F=9.8 p<0.01) were also significant. Post hoc analysis showed that 
100% catalepsy occurred only at a dose of 5.0 mg/kg of risperidone and 60% at 10.0 
mg/kg of clozapine. Clozapine did not decrease activity at a dose of 2.5 mg/kg but 
decreased it at doses of 5.0 mg/kg and 10.0 mg/kg. No catalepsy was observed at other 
doses of clozapine and risperidone. 
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Fig. 1.   Dose-response effects of clozapine and risperidone on locomotor activity and 
cataleptic potential in rats. Values are mean ± SD (n=12). Significant differences 
by Newman-Keuls test *p<0.05, **p<0.01 as compared to respective saline-
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Fig. 2.   Dose-response effects of clozapine and risperidone on DOPAC, DA, HVA and 
5-HIAA in rat caudate. Values are mean ± SD (n=12). Significant differences by 
Newman-Keuls test *p<0.05, **p<0.01 as compared to respective saline-treated 
rats following ANOVA. 
Figure 2 shows the dose-response effects of clozapine and risperidone on the levels of 
dopamine (DA), metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid 
(HVA), and 5-hydroxyindoleacetic acid (5-HIAA) in the caudate nucleus. ANOVA (df 3,12) 
showed significant effects of clozapine on the levels of DA (F=129.7 p<0.01), HVA (F=30.7 
p<0.01), DOPAC (F=6.3 p<0.05) and 5-HIAA (F=4.6 p<0.05). Effects of risperidone were 
also significant for HVA (F=7.1 p<0.05). Effects of risperidone on DA (F=1.2 p>0.05), 
DOPAC (F=1.1 p>0.05) and 5-HIAA (F=1.2 p>0.05) were not significant. Post hoc analysis 
showed effects of risperidone on DOPAC changes were not significant. Rats injected with 
2.5 mg/kg and 5.0 mg/kg exhibited pronounced 2-3 fold increases in HVA concentration 
and these increases were also comparable. HVA levels were also increased following the 266  F. Batool, M. A. Haleem and D. J. Haleem:   
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administration of clozapine and the increases maximum at a dose of 5.0 mg/kg. Maximum 
increases of HVA were greater in risperidone than clozapine injected animals. The 
concentration of DOPAC also increased following the administration of clozapine at a dose 
of 2.5 mg/kg and 5.0 mg/kg. DOPAC levels did not increase at cataleptogenic dose (10.0 
mg/kg) of clozapine. 5-HIAA levels increased following the administration of high dose of 
risperidone but these increases were not significant. Conversely, clozapine administration 
did decreased 5-HIAA concentration only at high dose of 10.0 mg/kg. The decreases not 
significant at doses of 2.5 mg/kg and 5.0 mg/kg were significant (p<0.01) at the 
cataleptogenic dose of 10.0 mg/kg. 
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Fig. 3.   Dose-response effects of clozapine and risperidone on DOPAC, DA, HVA and 
5-HIAA in rat nucleus accumbens. Values are mean ± SD (n=12). Significant 
differences by Newman-Keuls test *p<0.05, **p<0.01 as compared to respective 
saline-treated rats following ANOVA.   Relationship of Clozapine and Risperidone in Caudate and Nucleus Accumbens  267 
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Figure 3 shows the dose-response effects of clozapine and risperidone on the levels of 
DOPAC, DA, HVA and 5-HIAA in rat brain nucleus accumbens. ANOVA (df 3,12) showed 
significant effect of clozapine on DOPAC (F=64.5 p<0.01), DA (F=15.6 p<0.01), HVA 
(F=19.5 p<0.01) and 5-HIAA (F=14.5 p<0.01) concentrations. Effects of risperidone were 
significant for DOPAC (F=12.5 p<0.01) and HVA (F=27.8 p<0.01). Non-significant effects 
of risperidone were observed for DA (F=1.7 p>0.05) and 5-HIAA (F=34.6 p<0.01). Post 
hoc comparison showed that clozapine significantly (p<0.01) decreased concentrations of 
DOPAC, HVA and 5-HIAA in a dose-dependent manner. Levels of DA significantly 
(p<0.01) significantly increased at doses of 2.5 mg/kg and 10.0 mg/kg of clozapine. Levels 
of DA and 5-HIAA remained insignificant at all the doses of risperidone.  
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Fig. 4.   Dose-response effects of clozapine and risperidone on Tryptophan, HVA/DA 
and DOPAC/DA ratios in rat caudate and nucleus accumbens. Values are mean 
± SD (n=12). Significant differences by Newman-Keuls test *p<0.05, **p<0.01 
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Figure 4 shows the dose-response effects of clozapine and risperidone on the levels of 
tryptophan and the ratios of HVA/DA and DOPAC/DA in the rat caudate and nucleus 
accumbens. ANOVA (df 3,12) performed on caudate data showed insignificant effect of 
clozapine (F=2.1 p>0,05) and risperidone (F=4.6 p<0.05) for TRP. ANOVA (df 3,12) 
performed on data of nucleus accumbens also showed insignificant effect of clozapine 
(F=0.49 p>0,05) and risperidone (F=3.37 p>0.05) for TRP. Data analyzed for caudate 
showed significant effects of clozapine for HVA/DA (F=15.1 p<0.01) and risperidone 
(F=33.2 p<0.01). Data on nucleus accumbens showed significant effect of clozapine on 
DOPAC/DA ratio (F=10.34 p<0.01) and risperidone (F=9.46 p<0.01). Post hoc analysis 
showed that the caudate ratio of HVA/DA decreased significantly (p<0.01) in a dose-
dependent manner. Conversely, levels of DOPAC/DA ratio were significantly (p<0.01) 
increased in nucleus accumbens by all the doses of clozapine and risperidone.  
Discussion 
In the present study, atypical antipsychotic drugs, or so-called second-generation 
antipsychotics, like clozapine and risperidone, are defined as prototype agents causing low 
incidence of EPS in laboratory animals at doses that demonstrate antipsychotic activity. 
Management of extrapyramidal side effects (EPS) is a major concern of clinicians who use 
antipsychotic drugs. The incidence of motor side effects is dose dependent. The distinction 
between typical and atypical antipsychotic drugs has attained a considerable importance 
now. Moreover, the 5-HT2A/D2 hypothesis has contributed to the development of most of 
the current generation of atypical antipsychotic agents, including risperidone, olanzapine, 
quetiapine, ziprasidone, melperone and perospirone, all of which have a higher affinity for 
5-HT2A than for D2  receptors [16,  27–31]. Atypicality has been ascribed to 5-HT2/ D2 
antagonism that may be involved with the antipsychotic effect [2, 20]. The typical effect of 
administering a DA-D2 receptor antagonist is a suppression of spontaneous locomotor 
behavior and elicitation of a state known as catalepsy in laboratory animals [4, 22]. In the 
present study, all the doses of clozapine and risperidone we used were found to decrease 
motor activity in a dose-dependent manner (Fig. 1). Both drugs were found cataleptogenic 
only at high doses. However, effects of both drugs on locomotor activity in a familiar 
environment were comparable at all the doses. 
A major finding of the present study is that acute administration of risperidone relatively 
uniformly increases DA release and metabolism in the caudate region of rat brain. It is now 
generally agreed that clinical response to neuroleptics is associated with an increase in 
HVA concentration [24]. The proposed mechanism of HVA changes involves acute 
blockade of pre and postsynaptic D2 receptors in caudate. The presynaptic blockade 
increases the amount of DA released on subsequent action potentials, but because D2 
postsynaptic receptors are also blocked, acute DA transmission is attenuated. In addition, 
it is possible that the relative lack of EPS motor effects with clozapine and risperidone 
administration in the present study could be related to two-way interaction of drugs 
towards DA and 5-HT receptors.  
It is suggested from the present findings that the agents increasing dopamine transmission 
inhibits neuroleptic-induced catalepsy. The caudate and nucleus accumbens have been 
implicated as the major brain structures involved in antipsychotic induced catalepsy, which 
appears due to the blockade of dopamine neurotransmission. Animal studies suggest that 
the nucleus accumbens is the critical region in which both typical and atypical   Relationship of Clozapine and Risperidone in Caudate and Nucleus Accumbens  269 
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antipsychotic drugs exert their antipsychotic effects [25]. It was shown in early studies that 
administration of antipsychotic drugs increased DA turnover in rat brain [25]. Later studies, 
generally addressed DA release, show an increase in DA release in regions rich in DA 
terminals [23, 25]. It has been shown that blockade of pre- and postsynaptic receptors by a 
single injection of neuroleptics leads to an increase in the spike discharge of neurons 
belonging to the nigrostriatal system of the rat brain. It has been suggested that increased 
DA release in the caudate under the influence of neuroleptics can make a definite 
contribution to the formation of atypical pharmacologic profiles of these substances due to 
competition between the released mediator and neuroleptics at the level of postsynaptic 
DA receptors [23].  
The present study shows that administration of both clozapine and risperidone increased 
HVA concentration in the caudate (Fig. 2). Risperidone was more effective than clozapine 
in producing this effect in the caudate region. DOPAC the other metabolite of DA 
increased at noncataleptogenic doses of clozapine whereas, risperidone did not alter 
DOPAC concentration in the caudate. 5-HIAA levels were decreased at cataleptogenic 
dose (10.0 mg/kg) of clozapine and noncataleptogenic doses (1.0 & 2.5 mg/kg) of 
risperidone in caudate. Conversely, administration of clozapine and risperidone 
significantly decreased levels of DOPAC and HAV in the nucleus accumbens dose-
dependently (Fig.  3). 5-HIAA levels were also significantly decreased by clozapine 
administration in a dose-dependent manner. Cataleptogenic dose (10.0 mg/kg) of 
clozapine significantly increased DA levels in nucleus accumbens. Overall impact of 
clozapine and risperidone administration suggests that DA metabolism in caudate region 
was more responsive in evaluating the cataleptic potential of the drugs as compared to 
nucleus accumbens. Both drugs did not alter levels of TRP in caudate and nucleus 
accumbens. However, significant dose-dependent decreases were observed in caudate 
HVA/DA ratio following the administration of clozapine and risperidone. On the other hand, 
DOPAC/DA ratio in the nucleus accumbens were significantly increased at all the doses of 
clozapine and risperidone (Fig. 4). The present results also show that clozapine-induced 
increases of DA metabolism largely take place in the caudate than in the nucleus 
accumbens. Comparable effects of clozapine and risperidone on DA metabolism are at 
least, partly explicable in terms of their activities at DA and 5-HT receptors. Clozapine has 
a lower affinity for D2 receptors and risperidone has high affinity for 5-HT2 receptors. In 
vitro data indicate that clozapine is approximately equipotent at D1 and D2 receptors [27]. 
Other authors have also reported regional differences in D2 affinity of clozapine [28]. A role 
of D4 receptors has also been implicated in the mechanism of action of clozapine. The 
drug has high affinity for D4 receptors, higher than its affinity for D2 receptors [27, 28]. 
Another distinguished feature of the pharmacology of clozapine is its high affinity for 
serotonin receptors particularly 5-HT2A and 5-HT2C sites. This pharmacological profile of 
the drug is often linked with its therapeutic profile and lower incidence of EPS as observed 
in present study.  
There is now considerable evidence from studies of schizophrenia and other forms of 
psychoses, e.g., senile psychoses and L-DOPA psychoses, that a number of atypical 
antipsychotic agents such as clozapine and risperidone have also been found to have 
greater affinity for 5-HT2A than D2 receptors in vitro and are more effective with fewer side 
effects. The serotonergic effects of clozapine also have been emphasized as possibly 
being related to the unique clinical characteristics of clozapine [31], and recently it was 270  F. Batool, M. A. Haleem and D. J. Haleem:   
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suggested that the 5-HT2A/ D2 binding ratio could be used to distinguish between typical 
and atypical antipsychotics [32]. A decrease in 5-HT turnover by clozapine is explicable in 
terms of drugs moderate affinity for 5-HT1A receptors [32, 33]. Antipsychotic-like effects of 
clozapine are also often explained in terms of 5-HT1A agonist activity of the drug [33]. 
5-HT1A agonists decrease 5-HT turnover in various brain regions because of the 
stimulation of receptors located on cell body dendrites [34]. There is evidence that 5-HT1A 
agonist activity is involved in clozapine’s beneficial clinical profile and lower incidence of 
EPS. Thus postsynaptic 5-HT1A receptors were up regulated in postmortem schizophrenic 
patients [34]. 5-HT1A agonists have been shown to reverse haloperidol-induced catalepsy 
[35]. A comparison of the effects of two drugs shows that an increase in HVA 
concentration in the caudate (Fig. 2) and an increase in DOPAC/DA ratio in nucleus 
accumbens (Fig. 4) may be taken as a neurochemical profile of atypical, clozapine like, 
activity. Other authors have reported significant increases in caudate-putamen volumes in 
animals receiving either haloperidol or clozapine when compared with control animals 
following eight months of drug administration [36]. It is suggested that the neuroplastic 
response of the striatum following neuroleptic exposure causes volumetric increases, 
whereas atypical antipsychotics affect the basal ganglia differentially suggesting that such 
differential responses may be due to both the pharmacological properties and the relative 
doses of the atypical agents. 
In conclusion, the present study shows that administration of both clozapine and 
risperidone increased DA metabolism more in caudate than in nucleus accumbens in a 
dose-dependent manner. Consequently, our findings demonstrate a pharmacological 
profile of risperidone, as reflected in brain DA metabolism, with that of clozapine as a 
reference atypical compound. The preferential activation of DA release and metabolism in 
caudate and nucleus accumbens areas might be of particular relevance for the 
ameliorating effect of risperidone on negative symptoms in schizophrenia, especially when 
associated with depression. It is imperative to monitor for the emergence of EPS and TD in 
future studies, so that patients are not distressed or uncomfortable, and to facilitate 
adherence with ongoing antipsychotic therapy in patients with schizophrenia or other major 
psychiatric illnesses. 
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